Overview
U.S. medical aesthetics firm's Q4 revenue fell 1% yr/yr but beat analyst expectations
Adjusted EBITDA for Q4 beat analyst expectations, reflecting improved operational efficiency
Company posted Q4 net loss, but losses narrowed from prior year on lower expenses
Outlook
BeautyHealth sees Q1 2026 net sales of $63 mln to $68 mln
Company expects Q1 2026 adjusted EBITDA of $3.5 mln to $5.5 mln
BeautyHealth sees 2026 net sales of $285 mln to $305 mln
Company expects 2026 adjusted EBITDA of $35 mln to $45 mln
Company expects first-half 2026 revenue to be modestly below first-half 2025, with improvement in second half
Result Drivers
DELIVERY SYSTEMS DECLINE - Co said lower delivery systems net sales drove overall revenue decrease in Q4
CONSUMABLES SALES MIX - Gross margin improvement was primarily due to favorable mix shift towards consumable net sales and lower inventory related charges
LOWER OPERATING EXPENSES - Reduced personnel-related and marketing expenses contributed to lower operating costs
Company press release: ID:nGNX5lH1l0
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$82.4 mln
$77.80 mln (9 Analysts)
Q4 EPS
-$0.06
Q4 Net Income
-$8.1 mln
Q4 Adjusted EBITDA
Beat
$15 mln
$8.26 mln (7 Analysts)
Q4 Adjusted Gross Margin
67.4%
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the personal products peer group is "buy."
Wall Street's median 12-month price target for Beauty Health Co is $1.63, about 44.4% above its March 11 closing price of $1.13
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)